cytarabine + etoposide + ifosfamide + rituximab

This is a combination chemotherapy regimen consisting of four drugs—cytarabine, etoposide, ifosfamide, and rituximab—used primarily for the treatment of aggressive B-cell non-Hodgkin lymphomas such as Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL), particularly in CD20-positive cases. The regimen is often used in older patients (66 years and above) or those with poor performance status. Cytarabine is an antimetabolite that inhibits DNA synthesis; etoposide is a topoisomerase II inhibitor causing DNA strand breaks; ifosfamide is an alkylating agent that crosslinks DNA; rituximab is a monoclonal antibody targeting CD20 on B cells leading to their depletion. The combination aims for radical or curative intent in eligible patients[1][2][3].

Other names

RIVACR-IVAD